Editorial & Opinion
TOLLIP SNP and Antimicrobial Treatment Effect in Idiopathic Pulmonary Fibrosis.
| العنوان: | TOLLIP SNP and Antimicrobial Treatment Effect in Idiopathic Pulmonary Fibrosis. |
|---|---|
| المؤلفون: | Whalen W; Division of Pulmonary and Critical Care, Department of Medicine., Berger K; Division of Pulmonary and Critical Care, Department of Medicine., Kim JS; Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia., Simmons W; Division of Biostatistics, Department of Population Health Sciences, and., Ma SF; Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia., Kaner RJ; Division of Pulmonary and Critical Care, Department of Medicine.; Department of Genetic Medicine, New York Presbyterian-Weill Cornell Medicine, New York, New York., Martinez FJ; Division of Pulmonary and Critical Care, Department of Medicine., Anstrom KJ; University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina., Parfrey H; University of Cambridge and Royal Papworth Hospital National Health Service Foundation Trust, Cambridge, United Kingdom., Maher TM; University of Southern California, Los Angeles, California.; National Heart and Lung Institute, Imperial Biomedical Research Centre, and National Institute for Health and Care Research Margaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London, London, United Kingdom., Hammond M; Norwich Clinical Trials Unit and., Clark AB; Norwich Clinical Trials Unit and., Thickett D; Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom., Jenkins RG; National Heart and Lung Institute, Imperial Biomedical Research Centre, and National Institute for Health and Care Research Margaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London, London, United Kingdom., Wilson AM; Norwich Medical School, University of East Anglia, Norwich, United Kingdom; and., Noth I; Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia. |
| المصدر: | American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2024 Aug 15; Vol. 210 (4), pp. 508-511. |
| نوع المنشور: | Letter |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Thoracic Society Country of Publication: United States NLM ID: 9421642 Publication Model: Print Cited Medium: Internet ISSN: 1535-4970 (Electronic) Linking ISSN: 1073449X NLM ISO Abbreviation: Am J Respir Crit Care Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2000- : New York, NY : American Thoracic Society Original Publication: New York, NY : American Lung Association, c1994- |
| مواضيع طبية MeSH: | Idiopathic Pulmonary Fibrosis*/drug therapy , Polymorphism, Single Nucleotide*, Humans ; Male ; Female ; Aged ; Middle Aged ; Treatment Outcome ; Anti-Bacterial Agents/therapeutic use ; Anti-Infective Agents/therapeutic use ; Intracellular Signaling Peptides and Proteins |
| References: | Am J Respir Crit Care Med. 2017 Jul 15;196(2):208-219. (PMID: 28157391) J Mol Med (Berl). 2021 Jan;99(1):21-31. (PMID: 33128579) Am J Respir Crit Care Med. 2017 Jun 15;195(12):1640-1650. (PMID: 28085486) Am J Respir Crit Care Med. 2024 May 1;209(9):1101-1110. (PMID: 38051927) N Engl J Med. 2014 May 29;370(22):2071-82. (PMID: 24836310) JAMA. 2021 May 11;325(18):1841-1851. (PMID: 33974018) Am J Respir Crit Care Med. 2015 Dec 15;192(12):1475-82. (PMID: 26331942) Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211042529. (PMID: 34515605) Lancet Respir Med. 2013 Jun;1(4):309-317. (PMID: 24429156) FASEB J. 2020 Aug;34(8):9884-9898. (PMID: 32596871) J Thorac Dis. 2017 Nov;9(11):4376-4386. (PMID: 29268507) Lung India. 2011 Jul;28(3):174-9. (PMID: 21886950) N Engl J Med. 2014 May 29;370(22):2083-92. (PMID: 24836312) J Biol Chem. 2002 Mar 1;277(9):7059-65. (PMID: 11751856) Respiration. 2011;81(5):420-30. (PMID: 21502778) Pulmonology. 2024 Feb 2;:. (PMID: 38309995) Sci Rep. 2021 Aug 10;11(1):16250. (PMID: 34376770) JAMA. 2020 Dec 8;324(22):2282-2291. (PMID: 33289822) Am J Respir Crit Care Med. 2019 Jul 15;200(2):125-127. (PMID: 31113211) J Immunol. 2012 Aug 15;189(4):1737-46. (PMID: 22778396) Lancet Respir Med. 2014 Jul;2(7):548-56. (PMID: 24767767) |
| معلومات مُعتمدة: | United States HL NHLBI NIH HHS; United States Sunovion; Research Grant in Pulmonary Fibrosis United States CHEST Foundation; United States Stony Wold - Herbert Fund; United States Teva Pharmaceutical Industries; K23-HL-150301 United States GF NIH HHS; R01HL162659 United States GF NIH HHS; R01HL171918 United States GF NIH HHS; T32 HL134629 United States GF NIH HHS; T32-HL134629 United States GF NIH HHS; UG3HL145266 United States GF NIH HHS; United States Regeneron Pharmaceuticals; United States Sanofi; United States GlaxoSmithKline; United States Polarean; United States Novartis; United States Boehringer Ingelheim; United States Chiesi |
| المشرفين على المادة: | 0 (TOLLIP protein, human) 0 (Anti-Bacterial Agents) 0 (Anti-Infective Agents) 0 (Intracellular Signaling Peptides and Proteins) |
| تواريخ الأحداث: | Date Created: 20240519 Date Completed: 20240815 Latest Revision: 20240830 |
| رمز التحديث: | 20240830 |
| مُعرف محوري في PubMed: | PMC11351790 |
| DOI: | 10.1164/rccm.202312-2224LE |
| PMID: | 38762791 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1535-4970 |
|---|---|
| DOI: | 10.1164/rccm.202312-2224LE |